A California-based biotech company is finding early success on Tuesday after the company announced positive preliminary data of Vebreltinib in patients with non-CNS met fusion...

To read the full story on AllPennyStocks.com, click here.

Apollomics (NASDAQ:APLM)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025 Click aqui para mais gráficos Apollomics.
Apollomics (NASDAQ:APLM)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025 Click aqui para mais gráficos Apollomics.